Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~Subjects who have provided written informed consent and an authorization for disclosure of protected health information must meet the following criteria:~1. Healthy adult men or women, 18 to 60 (inclusive) years of age.~2. Have provided written informed consent prior to screening procedures.~3. Free of clinically significant health problems, as determined by pertinent medical history, physical examination without significant findings in the 28 days prior to enrollment, and clinical judgment of the Investigator.~4. Agrees not to have, or plan to have, non-study vaccines within 60 days after receiving the initial study vaccine, unless medically indicated (i.e., tetanus, rabies vaccine).~5. Agrees not to have contact with ruminant animals or other hoofed animals such as horses, pigs and cows 7 days after each vaccination.~6. Available, able, and willing to participate for all study visits and procedures through Day 182 (Week 26).~7. Be willing to minimize blood and body fluid exposure of others for 7 days after vaccination by:~   * using effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse;~  * avoiding the sharing of needles, razors, or toothbrushes; and~  * avoiding open mouth kissing.~8. Body mass index (BMI) less than 40 kg/m2.~9. Laboratory criteria without clinically significant findings within 28 days prior to enrollment:~   * hemoglobin ≥11.5 g/dL for women and ≥13.5 g/dL for men.~  * white blood cell count ≥3500 cells/mm3.~  * differential either within institutional normal range or accompanied by site physician approval;~  * platelets within normal limits;~  * alanine aminotransferase (ALT) or aspartate aminotransferase (AST) and alkaline phosphatase within upper limit of normal range or as approved by the Investigator; and~  * serum creatinine within upper limit of normal range or as approved by the Investigator.~10. Negative for Food and Drug Administration (FDA) approved HIV blood test.~11. Negative hepatitis B surface antigen (HbsAg).~12. Negative antibody to hepatitis C virus (antiHCV).~13. Normal urinalysis defined as negative or trace glucose, protein, and blood (non-menstruating females) by dipstick.~14. Negative urine pregnancy test for women of childbearing potential.~15. Non-pregnant, non-lactating females must meet one of the following criteria: no reproductive potential because of menopause (one year without menses) or because of a hysterectomy, bilateral oophorectomy, or tubal ligation; or subject agrees to be heterosexually inactive at least 21 days prior to enrollment and throughout the duration of the study; or agrees to consistently practice contraception at least 21 days prior to enrollment and throughout the duration of the study by one of the following methods: abstinence, condoms (male or female with or without a spermicide), diaphragm or cervical cap with spermicide, intrauterine device, contraceptive pills or patch, Norplant, Depo-Provera or other FDA approved contraceptive method, or male partner has previously undergone a vasectomy as declared in medical history.~EXCLUSION CRITERIA:~Any subject who meets any of the following criteria will not qualify for entry into the study:~1. History of prior infection with a filovirus or prior participation in a filovirus vaccine trial.~2. History of prior infection with VSV or receipt of a VSV vectored vaccine.~3. Has traveled to an area where the World Health Organization (WHO) has declared as an Ebola outbreak zone.~4. Healthcare worker who has direct contact with patients (nurse, physician, dentist, emergency medical technician, dental hygienist).~5. Has a household contact (HHC) who is immunodeficient, on immunosuppressive medications, HIV positive, pregnant or breast-feeding, or has an unstable medical condition.~6. Breast-feeding, or is a childcare worker, or HHC, who has direct contact with children, 5 years of age or younger.~7. Direct hands-on job preparing food in the food industry.~8. History of employment in an industry involved in contact with ruminant animals, other hoofed animals such as pigs and horses, veterinary sciences, or other potential exposure to VSV.~9. History of employment or activity that involves potential contact with filoviruses.~10. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.~11. Known allergy to any rVSVN4CT1 vectored vaccine component.~12. Receipt of investigational product (IP) up to 30 days prior to randomization or ongoing participation in another clinical trial except observational studies.~13. Receipt of licensed non-live or live vaccines within 30 days prior to planned study immunization.~14. Ability to observe possible local reactions at the eligible injection sites (deltoid region) is, in the opinion of the Investigator, unacceptably obscured due to a physical condition or permanent body art.~15. Acute or chronic, clinically significant dermatologic, psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the Investigator based on medical history, physical examination, and/or laboratory screening test. This would include a known autoimmune arthritis, hemoglobinopathy or coagulation abnormality as judged by the Investigator.~16. Leukopenia due to a clinical or pathological process, unless leukopenia is directly attributable to a transient process (e.g., acute viral infection) and resolution has been documented at time of enrollment.~17. Any screening or baseline laboratory test which in the opinion of the Investigator, is considered clinically significant.~18. Any cytotoxic therapy in the previous 5 years.~19. Diabetes mellitus (type I or II), with the exception of previous gestational diabetes.~20. Any chronic or active neurologic disorder, such as migraines (including silent), seizures or epilepsy (excluding a single febrile seizure as a child as judged by the Investigator).~21. Have a known history of Guillain Barré Syndrome (GBS).~22. Have an active malignancy or history of metastatic or hematologic malignancy.~23. Suspected or known alcohol and/or illicit drug abuse within the past 5 years per the judgment of the Investigator.~24. Moderate or severe illness and/or fever \>100.4 °F within 1 week prior to vaccination (subjects can be rescheduled).~25. Administration of immunoglobulin G (IgGs) and/or any blood products within the 120 days preceding study entry or planned administration during the study period.~26. History of blood donation within 60 days of enrollment or plans to donate within the study period.~27. Administration of chronic (defined as more than 14 days) immunosuppressants or other immune modifying drugs within 6 months of study entry: for corticosteroids, this includes chronic oral \>14 days or intraarticular steroids in the past 6 months (intranasal and topical are allowed).~28. Major surgery or hospitalization planned during the period of study participation.~29. Research staff or the immediate family of research staff directly involved with the clinical study.~30. Any other significant finding that in the opinion of the Investigator that would increase the risk of the individual having an adverse outcome from participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Ebola Vaccine - low dose (Type: EXPERIMENTAL): Low Dose Zaire Ebola Vaccine
- Ebola Vaccine - mid dose (Type: EXPERIMENTAL): Mid Dose Zaire Ebola Vaccine
- Ebola Vaccine - high dose (Type: EXPERIMENTAL): High Dose Zaire Ebola Vaccine
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete